Ferric carboxymaltose improves exercise capacity and quality of life in patients with pulmonary arterial hypertension and iron deficiency: A pilot study

International Journal of Cardiology

Volumn 175, Issue 2, 2014, Pages 233-239

  Viethen, Thomas ^a   Gerhardt, Felix ^a   Dumitrescu, Daniel ^a   Knoop Busch, Susanne ^a   Ten Freyhaus, Henrik ^a   Rudolph, Tanja K ^a   Baldus, Stephan ^a   Rosenkranz, Stephan ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

Author keywords

Ferric carboxymaltose; Iron; Iron deficiency; Pulmonary arterial hypertension (PAH)

Indexed keywords

FERRIC CARBOXYMALTOSE; FERRITIN; IRON; TRANSFERRIN; FERRIC ION; MALTOSE;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DRUG TOLERABILITY; EXERCISE; EXERCISE TEST; FEMALE; FERRITIN BLOOD LEVEL; HEART CATHETERIZATION; HOMEOSTASIS; HUMAN; IRON ABSORPTION; IRON BLOOD LEVEL; IRON DEFICIENCY; LUNG WEDGE PRESSURE; MALE; MORTALITY; PILOT STUDY; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; PULMONARY HYPERTENSION; QUALITY OF LIFE; RATING SCALE; SCORING SYSTEM; TRANSFERRIN BLOOD LEVEL; TRANSTHORACIC ECHOCARDIOGRAPHY; AGED; ANALOGS AND DERIVATIVES; ANEMIA, IRON-DEFICIENCY; HYPERTENSION, PULMONARY; INTRAVENOUS DRUG ADMINISTRATION; MIDDLE AGED; PATHOPHYSIOLOGY; PROCEDURES;

AGED; ANEMIA, IRON-DEFICIENCY; EXERCISE TEST; FEMALE; FERRIC COMPOUNDS; HUMANS; HYPERTENSION, PULMONARY; INFUSIONS, INTRAVENOUS; MALE; MALTOSE; MIDDLE AGED; PILOT PROJECTS; PROSPECTIVE STUDIES; QUALITY OF LIFE;

EID: 84904268951     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2014.04.233     Document Type: Article

References (38)

1. M. Hoeper, H.J. Bogaard, and R. Condliffe et al. Definition and diagnosis of pulmonary hypertension J Am Coll Cardiol 62 Suppl. D 2013 D42 D50
2. N. Galiè, M.M. Hoeper, and M. Humbert et al. Guidelines for the diagnosis and treatment of pulmonary hypertension: The Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT) Eur Heart J 30 2009 2493 2537
3. V.V. McLaughlin, S.L. Archer, and D.B. Badesch et al. ACCF/AHA 2009 expert consensus document on pulmonary hypertension: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association developed in collaboration with the American College of Chest Physicians; American Thoracic Society, Inc.; and the Pulmonary Hypertension Association J Am Coll Cardiol 53 2009 1573 1619
4. R.L. Benza, D.P. Miller, and M. Gomberg-Maitland et al. Predicting survival in pulmonary arterial hypertension: insights from the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL) Circulation 122 2010 164 172
5. M. Humbert, O. Sitbon, and A. Chaouat et al. Survival in patients with idiopathic, familial, and anorexigen-associated pulmonary arterial hypertension in the modern management era Circulation 122 2010 156 163
6. M.M. Hoeper, D. Huscher, and A.H. Ghofrani et al. Idiopathic pulmonary arterial hypertension in the elderly: results from the COMPERA registry Int J Cardiol 168 2013 871 880
7. N. Galiè, P.A. Corris, and A. Frost et al. Updated treatment algorithm of pulmonary arterial hypertension J Am Coll Cardiol 62 Suppl. D 2013 D60 D72
8. H.A. Ghofrani, O. Distler, and F. Gerhardt et al. Treatment of pulmonary arterial hypertension: updated recommendations of the Cologne Consensus Conference 2011 Int J Cardiol 154 Suppl. 2011 S20 S33
9. G. Ruiter, S. Lankhorst, A. Boonstra, and A. Vonk-Noordegraaf et al. Iron deficiency is common in idiopathic pulmonary arterial hypertension Eur Respir J 37 2011 1386 1391
10. E. Soon, C.M. Treacy, and M.R. Toshner et al. Unexplained iron deficiency in idiopathic and heritable pulmonary arterial hypertension Thorax 66 2011 326 332
11. C.J. Rhodes, L.S. Howard, and M. Busbridge et al. Iron deficiency and raised hepcidin in idiopathic pulmonary arterial hypertension: clinical prevalence, outcomes and mechanistic insights J Am Coll Cardiol 58 2011 300 309
12. C.V. Hampole, A.K. Mehrotra, T. Thenappan, M. Gomberg-Maitland, and S.J. Shah Usefulness of red cell distribution width as a prognostic marker in pulmonary hypertension Am J Cardiol 104 2009 868 872
13. R. Krasuski, S. Hart, B. Smith, A. Wang, J. Harrison, and T. Bashore Association of anaemia and long-term survival in patients with pulmonary hypertension Int J Cardiol 150 2010 291 295
14. G. Ruiter, I.J. Lanser, and F.S. de Man et al. Iron deficiency in systemic sclerosis patients with and without pulmonary hypertension Rheumatology 53 2014 285 292
15. S. Anker, J. Comin Colet, and G. Filippatos et al. Ferric carboxymaltose in patients with heart failure and iron deficiency N Engl J Med 36125 2009 2436 2448
16. M.W. Hentze, M.U. Muckenthaler, B. Galy, and C. Camaschella Two to tango: regulation of mammalian iron metabolism Cell 142 2010 24 38
17. L.G. Rudski, W.W. Lai, and J. Afilalo et al. Guidelines for the echocardiographic assessment of the right heart in adults: a report from the American Society of Echocardiography endorsed by the European Association of Echocardiography, a registered branch of the European Society of Cardiology, and the Canadian Society of Echocardiography J Am Soc Echocardiogr 7 2010 685 713
18. K. Wasserman, J.E. Hansen, and D.Y. Sue et al. Measurements during integrative cardiopulmonary exercise testing Principles of exercise testing and interpretation 5th ed 2012 Lippincott Williams & Wilkins Philadelphia 71 103
19. ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories ATS statement: guidelines for the six-minute walk test Am J Respir Crit Care Med 166 2002 111 117
20. P. Geisser, M. Baer, and E. Schaub Structure/histotoxicity relationship of parenteral iron preparations Arzneimittelforschung 42 1992 1439 1452
21. A.M. Ganzoni Intravenous iron-dextran: therapeutic and experimental possibilities Schweiz Med Wochenschr 100 1970 301 303
22. C.A. Finch, L.R. Miller, and A.R. Inamdar et al. Iron deficiency in the rat. Physiological and biochemical studies of muscle dysfunction J Clin Invest 58 1976 447 453
23. V. Mainguy, F. Maltais, and D. Saey et al. Peripheral muscle dysfunction in idiopathic pulmonary arterial hypertension Thorax 65 2010 113 117
24. G. Filippatos, D. Farmakis, and J.C. Colet et al. Intravenous ferric carboxymaltose in iron-deficient chronic heart failure patients with and without anaemia: a subanalysis of the FAIR-HF trial Eur J Heart Fail 15 2013 1267 1276
25. J.J. McMurray, S. Adamopoulos, and S.D. Anker et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012 Eur Heart J 33 2012 1787 1847
26. K. Swedberg, J.B. Young, and I.S. Anand et al. Treatment of anemia with darbepoetin alfa in systolic heart failure N Engl J Med 368 2013 1210 1219
27. C. Atkinson, S. Stewart, and P.D. Upton et al. Primary pulmonary hypertension is associated with reduced pulmonary vascular expression of type II bone morphogenetic protein receptor Circulation 105 2002 1672 1678
28. F. Soubrier, W.K. Chung, and R. Machado et al. Genetics and genomics of pulmonary arterial hypertension J Am Coll Cardiol 63 Suppl. D 2013 D13 D21
29. B. Andriopoulos Jr., E. Corradini, and Y. Xia et al. BMP6 is a key endogenous regulator of hepcidin expression and iron metabolism Nat Genet 41 2009 482 487
30. S. Arndt, U. Maegdefrau, C. Dorn, K. Schardt, C. Hellerbrand, and A.K. Bosserhoff Iron-induced expression of bone morphogenic protein 6 in intestinal cells is the main regulator of hepatic hepcidin expression in vivo Gastroenterology 138 2010 372 382
31. S.C. Mattei, M.A. Puhan, D. Lam, and R.A. Wise The minimal important difference in the 6 minute walk test for patiens with pulmonary arterial hypertension Am J Respir Crit Care Med 186 2012 428 433
32. T. Pulido, I. Adzerikho, and R.N. Channick et al. for the SERAPHIN Investigators. Macitentan and morbidity and mortality in pulmonary arterial hypertension N Engl J Med 369 2013 809 818
33. H.A. Ghofrani, N. Galiè, and F. Grimminger et al. for the PATENT Investigators. Riociguat for the treatment of pulmonary arterial hypertension N Engl J Med 369 2013 330 340
34. C.M. Wong, I.R. Preston, N.S. Hill, and Y.J. Suzuki Iron chelation inhibits the development of pulmonary vascular remodeling Free Radic Biol Med 53 2012 1738 1747
35. T.G. Smith, N.P. Talbot, and C. Privat et al. Effects of iron supplementation and depletion on hypoxic pulmonary hypertension: two randomized controlled trials JAMA 302 2009 1444 1450
36. M.C. Ghosh, D.L. Zhang, and S.Y. Jeong et al. Deletion of iron regulatory protein 1 causes polycythemia and pulmonary hypertension in mice through translational depression of HIF2a Cell Metab 17 2013 271 281
37. D.G. MacArthur, S. Balasubramanian, and A. Frankish et al. A systematic survey of loss-of-function variants in human protein-coding genes Science 335 2012 823 828
38. J.D. Cook, S. Dassenko, and B.S. Skikne et al. Serum transferrin receptor as an index of iron absorption Br J Hematol 75 1990 603 609